Voyager Therapeutics Q3 2024 Update

TL;DR

Voyager Therapeutics has $178.4M cash, ongoing deals with Neurocrine & Novartis. Focus on R&D.

AI Summary

Voyager Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $178.4 million as of September 30, 2024. Key collaborations include agreements with Neurocrine Biosciences, Inc. and Novartis Pharma AG, with specific dates mentioned for these partnerships, such as the Neurocrine Collaborative Agreement in 2023 and the Novartis Collaboration Agreement in 2023.

Why It Matters

This filing provides insight into Voyager Therapeutics' financial health and ongoing research collaborations, which are crucial for its drug development pipeline.

Risk Assessment

Risk Level: medium — Biotech companies like Voyager Therapeutics are inherently risky due to the long and uncertain drug development process.

Key Numbers

• $178.4M — Cash and Cash Equivalents (As of September 30, 2024, indicating liquidity.)

Key Players & Entities

• Voyager Therapeutics, Inc. (company) — Filer
• $178.4 million (dollar_amount) — Cash and cash equivalents as of September 30, 2024
• September 30, 2024 (date) — Reporting period end date
• Neurocrine Biosciences, Inc. (company) — Collaborator
• Novartis Pharma AG (company) — Collaborator
• Todd Carter, Ph.D. (person) — Chief Scientific Officer

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select

Filing Documents

• vygr-20240930x10q.htm (10-Q) — 1635KB
• vygr-20240930xex10d1.htm (EX-10.1) — 57KB
• vygr-20240930xex10d2.htm (EX-10.2) — 32KB
• vygr-20240930xex31d1.htm (EX-31.1) — 13KB
• vygr-20240930xex31d2.htm (EX-31.2) — 13KB
• vygr-20240930xex32d1.htm (EX-32.1) — 10KB
• 0001558370-24-015304.txt ( ) — 6832KB
• vygr-20240930.xsd (EX-101.SCH) — 41KB
• vygr-20240930_cal.xml (EX-101.CAL) — 48KB
• vygr-20240930_def.xml (EX-101.DEF) — 189KB
• vygr-20240930_lab.xml (EX-101.LAB) — 361KB
• vygr-20240930_pre.xml (EX-101.PRE) — 298KB
• vygr-20240930x10q_htm.xml (XML) — 1251KB

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "contemplate," "anticipate," "goals," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our plans to develop and commercialize our product candidates based on adeno-associated virus, or AAV, gene therapy and our proprietary antibodies; our ability to continue to develop our proprietary gene therapy platform technologies, including our TRACER TM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) discovery platform and our vectorized antibody platform, our proprietary antibody program, and our gene therapy and vectorized antibody programs; our ability to identify and optimize product candidates and proprietary AAV capsids; our strategic collaborations and licensing agreements with, and funding from, our collaboration partners Neurocrine Biosciences, Inc. and Novartis Pharma AG, and our licensee Alexion, AstraZeneca Rare Di

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 5 CONDENSED CONSOLIDATED BALANCE SHEETS 5 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) Income 6 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 7 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 8 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 33 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 33

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 33 ITEM 1A.

RISK FACTORS

RISK FACTORS 34 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ITEM 5. OTHER INFORMATION 34 ITEM 6. EXHIBITS 35

SIGNATURES

SIGNATURES 36 4 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Voyager Therapeutics, Inc. Condensed Consolidated Balance Sheet s (amounts in thousands, except share and per share data) (unaudited) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 112,525 $ 68,802 Marketable securities, current 232,835 162,073 Accounts receivable 15,954 80,150 Related party collaboration receivable 3,714 3,341 Prepaid expenses and other current assets 8,415 5,318 Total current assets 373,443 319,684 Property and equipment, net 15,201 16,494 Deposits and other non-current assets 2,874 1,593 Operating lease, right-of-use assets 34,523 13,510 Total assets $ 426,041 $ 351,281 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,160 $ 1,604 Accrued expenses 11,442 16,823 Other current liabilities 6,979 3,200 Deferred revenue, current 22,629 42,881 Total current liabilities 44,210 64,508 Deferred revenue, non-current 12,153 32,359 Other non-current liabilities 39,368 18,094 Total liabilities 95,731 114,961 Commitments and contingencies (see note 7) Stockholders' equity: Preferred stock, $ 0.001 par value: 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value: 120,000,000 shares authorized at September 30, 2024 and December 31, 2023; 54,542,048 and 44,038,333 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 55 44 Additional paid-in capital 621,985 497,506 Accumulated other comprehensive loss ( 33 ) ( 48 ) Accumulated deficit ( 291,697 ) ( 261,182 ) Total stockholders' equity 330,310 236,320 Total liabilities and stockholders' equity $ 426,041 $ 351,281 The accompanying notes are an integral part of these condensed c onsolidated financial s

View Full Filing

View this 10-Q filing on SEC EDGAR